Welcome to our dedicated page for Axcella Health news (Ticker: AXLA), a resource for investors and traders seeking the latest updates and insights on Axcella Health stock.
Axcella Health Inc. (NASDAQ: AXLA) is an innovative biotechnology company dedicated to pioneering new therapeutic solutions through its proprietary Defined Amino Acid Compositions (DAACs™). These compositions harness the essential signaling capabilities of amino acids to address and rectify dysregulated pathways, offering safer treatments for patients with complex diseases.
With the groundbreaking Axcelerator™ platform, Axcella is revolutionizing traditional drug discovery and development. This platform allows for the generation of comprehensive patient data in less than a year from the selection of an indication, significantly accelerating the process of bringing new therapies to market. The Axcelerator™ platform has already produced a robust pipeline of clinical programs targeting a wide range of conditions, including liver diseases, metabolic disorders, central nervous system (CNS) diseases, and orphan diseases.
Recent achievements by Axcella include notable advancements in its clinical programs. The company has made significant strides in developing treatments for liver diseases and metabolic disorders, leveraging its DAAC-based therapies to provide innovative solutions where traditional treatments fall short.
As a forward-thinking entity in the biotech space, Axcella has forged key partnerships to enhance its research and development capabilities. These collaborations are pivotal in supporting the company’s mission to deliver effective and safe therapeutic options for patients with complex and underserved medical needs.
Financially, Axcella continues to focus on sustainable growth and development. The company is actively engaged in securing funding to support its research initiatives and clinical trials. With a commitment to transparency and progress, Axcella regularly updates its investors and stakeholders on its financial condition, strategic goals, and operational milestones.
In summary, Axcella Health Inc. stands at the forefront of biotechnological innovation, offering cutting-edge solutions through DAAC therapeutics and the Axcelerator™ platform. The company’s dedication to improving patient outcomes and its proactive approach to drug development position it as a significant player in the biotech industry.
Axcella (AXLA) reported its Q4 and full-year 2020 financial results, highlighting pivotal milestones in its clinical development. The company gained FDA IND clearance for AXA1665, targeting recurrent overt hepatic encephalopathy, and plans to initiate a Phase 2 trial in Q2 2021. Axcella also engaged with the FDA on AXA1125 for nonalcoholic steatohepatitis, setting the stage for a Phase 2b trial. Axcella's cash position rose to $107.3 million, sufficient to fund operations into Q3 2022. The company reported a net loss of $56.5 million for 2020, an improvement from 2019.
Axcella (Nasdaq: AXLA) announced plans to report its fourth quarter and full year 2020 financial results on March 17, 2021. The company will host a conference call at 8:30 a.m. ET, with details available on its website. Axcella focuses on treating complex diseases using endogenous metabolic modulator (EMM) compositions. Its pipeline includes candidates targeting non-alcoholic steatohepatitis (NASH) and the recurrence of overt hepatic encephalopathy (OHE).
Axcella (Nasdaq:AXLA) has appointed Dr. Alison D. Schecter as President of Research and Development, overseeing clinical and regulatory efforts as the company enters late-stage development with its lead candidates. Dr. Schecter brings over 20 years of experience, previously serving at Selecta Biosciences and Sanofi-Genzyme. Manu Chakravarthy has stepped down as Chief Medical Officer. Axcella is working on innovative therapies for complex diseases, including non-alcoholic steatohepatitis (NASH) and hepatic encephalopathy (OHE).
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, has announced three presentations at the NASH-TAG 2021 Conference on March 11-13. The highlights include clinical data on AXA1125, a candidate for nonalcoholic steatohepatitis (NASH), which is advancing into Phase 2b trials. Presentations will cover mechanistic insights into AXA1125 and its biological activity regarding glucose, insulin, liver fat, and fibroinflammation in subjects with NAFLD and type 2 diabetes. Nadege T. Gunn, M.D. will receive a Distinguished Abstract and Poster Award during the event.
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the 33rd Annual Roth Conference on March 15, 2021. Webcasts of these presentations will be available on the company’s website for 90 days. Axcella focuses on treating complex diseases using endogenous metabolic modulator compositions, with candidates targeting non-alcoholic steatohepatitis and hepatic encephalopathy.
Axcella (Nasdaq: AXLA) announced the FDA's clearance of its first investigational new drug (IND) filing, enabling the advancement of AXA1665 into Phase 2 trials. The company reported positive data from previous studies on AXA1665 and AXA1125, indicating their potential in treating overt hepatic encephalopathy (OHE) and nonalcoholic steatohepatitis (NASH) respectively. AXA1665's Phase 2 trial aims to enroll approximately 150 patients and assess its efficacy in reducing OHE risk. Axcella plans to expand its pipeline with further clinical trials slated for 2021.
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced its participation in the J.P. Morgan 2021 Healthcare Conference, scheduled for January 14, 2021, at 10:00 a.m. ET. The event will feature a live audio webcast available on the company’s website, with a replay accessible for 90 days post-presentation. Axcella focuses on treating complex diseases using endogenous metabolic modulator (EMM) compositions. Its pipeline includes candidates for non-alcoholic steatohepatitis (NASH) and reducing the risk of overt hepatic encephalopathy recurrence.
Axcella (NASDAQ: AXLA) presented data at The Liver Meeting® 2020 regarding AXA1125, a treatment candidate for nonalcoholic steatohepatitis (NASH). The clinical study, AXA1125-003, involved 102 subjects and showed promising results in safety and efficacy over 16 weeks. Key findings included significant reductions in metabolic markers and liver function indicators for patients receiving AXA1125 compared to placebo. Axcella aims to further explore AXA1125's impact on liver histology in an upcoming Phase 2b trial targeting biopsy-proven NASH.
Axcella (AXLA) reported its third-quarter financial results for 2020, showcasing significant advancements amidst the COVID-19 pandemic. The company successfully completed a Type B pre-IND meeting with the FDA for AXA1125, advancing towards an IND application and a Phase 2b trial for nonalcoholic steatohepatitis (NASH). Positive top-line data were also presented for AXA1665, targeting hepatic encephalopathy recurrence. Axcella's cash position improved to $117.3 million, and net losses decreased compared to the previous year. The company plans to initiate additional trials in 2021.
Axcella (AXLA), a clinical-stage biotechnology firm, will report its Q3 financial results and business updates on November 12, 2020. The conference call will begin at 8:30 a.m. ET and can be accessed via telephone or through a webcast on Axcella's website. The company focuses on treating complex diseases using endogenous metabolic modulator compositions, with lead candidates targeting non-alcoholic steatohepatitis and hepatic encephalopathy. Investors are encouraged to monitor the company's website for updates and disclosures.
FAQ
What is the market cap of Axcella Health (AXLA)?
What is Axcella Health Inc. known for?
What is the Axcelerator™ platform?
Which therapeutic areas does Axcella focus on?
How does Axcella’s DAAC therapeutics work?
What recent achievements has Axcella made?
Who are Axcella's key partners?
How does Axcella fund its research initiatives?
What is the significance of DAAC therapeutics?
What makes Axcella’s drug development process unique?
How does Axcella keep its stakeholders informed?
